Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary endpoint and the only time stamp out of 10 in which the candidate ...

Now, the candidate has failed to match Eylea in a phase 3 trial, leaving the Australian biotech to consider its own future. The drug in question is sozinibercept, an inhibitor of vascular ...

Teenagers under 18 years old would need written parental permission to use tanning beds at tanning salons in Iowa under a bill passed by the House.

House Bill 1393, which aims to give parents of children with IEPs more of a choice in their child’s education, is headed to the Senate for further consideration.

had infringed on U.S. Patent 11,084,865, claimed to cover a vial containing Eylea. As a result of the ruling, Amgen, which produces a biosimilar for Eylea, saw its shares increase by as much as 0.5%.

This arrangement, the lawsuit claims, effectively lowered Eylea's selling price and provided Regeneron with a competitive advantage in the anti-VEGF medication market. The Department of Justice ...

The TALON trial in the wet form of AMD will compare brolucizumab against Eylea (aflibercept) on a range of measures, including visual acuity and treatment interval duration, to see if it can ...

a form of the disease where abnormal blood vessels grow in the back of the eye. They all had severe disease and a high treatment burden with an average of 10 injections with Eylea (aflibercept), a ...

Another concern for Bayer is the oncoming loss of patent protection in Europe for eye disease treatment Eylea, which generated sales of 3.3 billion euros ($3.6 billion), good for a 2% increase.

Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen (NASDAQ:AMGN) in a patent case over Regeneron's blockbuster Eylea drug was affirmed by an appeals court.

1 Cash receipts for the year ended December 31, 2024 includes milestone royalty receipts of $2,104 from Orserdu I, $18,939 from Orserdu II and $5,000 from Vonjo II received in Q1 2024. 2Cash receipts ...